Aim: to evaluate a new tumour marker HE4, in comparison with CA 125 and the Risk of Ovarian cancer in pre and postmenopausal women with ovarian cancer.

Method: The ovarian cancer female patients were recruited from OPD/IPD of Surgery and Oncology department of SMS Hospital, and evaluated serum human epididymis protein (HE4) and CA125 Patients were divided into two group’s premenopausal and postmenopausal women with ovarian cancer.

Results: Serum HE4 and CA125 level significantly high in postmenopausal women as compared to premenopausal women of ovarian cancer. The result was significantly high. (p<0.001). AUC for CA125 was 0.680 (95% CI 0.587-0.773) and for HE4 was 0.893(0.95% CI0.840-0.946) (p=0.001) for distinguishing between ovarian cancer cases and control healthy subjects. HE4 showed positive correlation with CA125 (r=0.388, p=0.000). HE4 were significantly higher than CA125 in sensitivity and specificity (91% vs.82.3% and 94% vs 83%, respectively). Also the positive predictive values (PPV) and negative predictive values (NPV) for HE4 were significantly higher than CA125 (92.1% vs 79.1% and 91.7% vs 85.2%, respectively).

Conclusion: Serum HE4 level can predict ovarian cancer in postmenopausal women. Risk of ovarian cancer is increased with increase in HE4 level in postmenopausal women. HE4 level have more sensitivity and specificity compared with CA125 in diagnosing ovarian cancer.